Press coverage about Conatus Pharmaceuticals (NASDAQ:CNAT) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Conatus Pharmaceuticals earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.7958258015213 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

CNAT has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Conatus Pharmaceuticals in a research note on Thursday, June 29th. Stifel Nicolaus reissued a “buy” rating and set a $10.00 price objective on shares of Conatus Pharmaceuticals in a research note on Thursday, August 3rd. Seaport Global Securities reissued a “buy” rating and set a $16.00 price objective on shares of Conatus Pharmaceuticals in a research note on Friday, October 6th. Finally, Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Conatus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $16.17.

Conatus Pharmaceuticals (CNAT) traded down 1.94% during midday trading on Thursday, reaching $5.05. The company had a trading volume of 427,921 shares. The company’s market capitalization is $151.52 million. The firm has a 50-day moving average price of $5.58 and a 200-day moving average price of $5.85. Conatus Pharmaceuticals has a 52 week low of $1.45 and a 52 week high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $9.33 million. During the same period in the previous year, the business earned ($0.30) earnings per share. Analysts expect that Conatus Pharmaceuticals will post ($0.53) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Insider Buying and Selling by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.